Primary sclerosing cholangitis is a rare disease characterized by inflammation and scarring of the bile ducts that causes them to narrow. This leads to bile accumulation in the liver. Treatment primarily focuses on relieving symptoms and slowing disease progression. Drugs such as ursodeoxycholic acid and antibiotic therapy are commonly prescribed. Steroid medications may also be used. With no cure currently available, liver transplantation is often required in advanced cases.
The global primary sclerosing cholangitis market is estimated to be valued at US$ 250 million in 2023 and is expected to exhibit a CAGR of 5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of global primary sclerosing cholangitis market size is the major trend fueling the market growth. According to a study, the prevalence of primary sclerosing cholangitis varies from 0 to 16.2 per 100,000 persons. The prevalence is higher among Caucasians and increases with age. The signs and symptoms are often nonspecific which makes early diagnosis difficult. With growing awareness, early detection is improving which is leading to the growth of the primary sclerosing cholangitis market. Besides this, increasing research into new drug therapies is another key trend in the market. Many companies are conducting clinical trials to evaluate novel drugs that could modify disease progression or potentially cure it. This will offer lucrative development opportunities over the forecast period.
Segment Analysis
Primary sclerosing cholangitis is a chronic, progressive disease of the bile ducts within and outside the liver. The primary sclerosing cholangitis market is primarily segmented into drug class and end-users. Based on drug class, the ursodeoxycholic acid segment currently dominates the market as it is a FDA approved medication and the only drug approved for the treatment of primary sclerosing cholangitis. It helps in reducing bile acids in the liver and decrease symptoms.
Key Takeaways:
The global primary sclerosing cholangitis market is expected to witness high growth over the forecast period of 2023 to 2030 owing to the rising cases of inflammatory bowel diseases and increasing research funding for rare diseases. The global primary sclerosing cholangitis market is estimated to be valued at US$ 250 million in 2023 and is expected to exhibit a CAGR of 5% over the forecast period 2023 to 2030.
Regional analysis: North America is currently the dominant region in the primary sclerosing cholangitis market due to the high prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease in the region. Additionally, established healthcare infrastructure and awareness among people regarding rare diseases contribute to the large share of the region. Asia Pacific is anticipated to grow at the fastest rate during the forecast period owing to the improving healthcare facilities and rising medical expenditure in countries like China and India.
Key players: Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Dr. Falk Pharma GmbH, HighTide Therapeutics Inc., and Intercept Pharmaceuticals, Inc. Acorda Therapeutics, Inc. dominates the market with its FDA approved drug Inbrija which is used for treating OFF episodes in people with Parkinson’s disease.
Get More Insights On This Topic: https://www.newsstatix.com/primary-sclerosing-cholangitis-market-size-share-analysis-2023-2030/
